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Background: This systematic review and meta- analysis aimed to evaluate the effects 
of pharmacological agents for neurogenic oropharyngeal dysphagia based on evi-
dence from randomized controlled trials (RCTs).
Methods: Electronic	databases	were	systematically	searched	between	January	1970	
and	March	2021.	Two	reviewers	independently	extracted	and	synthesized	the	data.	
The outcome measure was changed in (any) relevant clinical swallowing- related 
characteristics.
Key results: Data	from	2186	dysphagic	patients	were	collected	from	14	RCT	stud-
ies across a range of pharmacotherapies. The pooled effect size of transient recep-
tor potential (TRP) channel agonists was large compared to placebo interventions 
(SMD[95%CI]	=1.27[0.74,1.80],	 p < 0.001; I2 =	 79%).	 Data	were	 limited	 for	 other	
pharmacological agents and the overall pooled effect size of these agents was non- 




[−2.32,0.99];	p = 0.43; I2 =	61%),	Physostigmine	 (SMD[95%CI]	=	−0.05[−1.03,0.93];	
p =	0.92)	and	Glyceryl	Trinitrate	(GTN)	(SMD	[95%	CI]	=	−0.01	[−0.11,	0.08];	p =	0.78)	
were	 non-	significant.	 Within	 stroke	 patients,	 subgroup	 analysis	 showed	 that	 TRP	
channel	agonists	had	a	moderate	pooled	effect	size	(SMD[95%CI]	=0.74[0.10,1.39];	
p = 0.02; I2 =	 82%)	 whereas	 the	 effects	 of	 other	 agents	 were	 non-	significant	
(SMD[95%CI]	=0.40[−0.04,0.84];	p =	0.07;	I2 =	87%).
Conclusions & Inferences: Our results showed that TRP channel agonists, Nifedipine 
and	 Metoclopromide	 may	 be	 beneficial	 for	 neurogenic	 dysphagic	 patients.	 Large	
scale,	multicenter	 clinical	 trials	 are	warranted	 to	 fully	 explore	 their	 therapeutic	 ef-
fects on swallowing.
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1  |  INTRODUC TION
Dysphagia is a symptom referring to difficulties in the passage of 
food	 or	 liquid	 from	 the	 mouth,	 through	 pharynx	 and	 esophagus,	
to the stomach.1 It can be anatomically classified into oropharyn-
geal dysphagia and esophageal dysphagia. Dysphagia affects ap-
proximately	56	million	people	worldwide2 and is prevalent among 
patients	with	stroke	(8%–	80%),	Parkinson's	disease	(11%–	81%)	and	
traumatic	 brain	 injury	 (27%–	30%),	 as	 well	 as	 community	 dwelling	
elderly	people	 (11%–	34%).3-	5	Malnutrition,	 dehydration,	 aspiration	
pneumonia,	prolonged	hospital	stay,	mealtime	anxiety	and	increased	
mortality are common physical and psychosocial consequences of 
dysphagia.6-	9	Moreover,	 the	 cost	 of	 healthcare	 resources	 is	 likely	
to be substantial for patients and to society in general due to their 
complex	nature.10,11 Dysphagia treatments are generally focused on 
improving safety and efficiency of swallowing. They can be compen-
satory, such as modifications of diet consistency or feeding posture, 
or	rehabilitative,	such	as	strength	or	skill	training	exercises	for	swal-
lowing musculature.12 Rehabilitative interventions also include acu-
puncture, peripheral sensory stimulation through thermal, tactile or 
electrical (neuromuscular or pharyngeal) stimulation or non- invasive 
brain stimulation including repetitive transcranial magnetic stimula-
tion	(rTMS)	or	transcranial	electrical	stimulation	(TES).12
Of importance to this field, pharmacological agents are a potential 
management option for dysphagia and yet they have received rela-
tively little attention compared to other treatments. These agents 
either stimulate swallowing- related neural pathways in the peripheral 
or central nervous systems or directly modifying muscular function.13 
To date, the drug classes that have been studied in the area of swal-
lowing and oropharyngeal dysphagia include transient receptor po-
tential vanilloid 1 (TRPV1) agonists,14- 20 transient receptor potential 
ankyrin 1 (TRPA1) agonists,21 transient receptor potential melastatin 
8	 (TRPM8)	 agonists,22 levodopa,23-	25 other dopaminergic agents,26 
calcium blocking agents,27,28 dopamine D2 receptor antagonists,29 
angiotensin- converting enzyme (ACE) inhibitors,30 beta blockers,31 
nitric	oxide	donors32 and acetylcholinesterase inhibitors.33
Studies	have	suggested	that	these	drugs	may	improve	the	swal-
lowing	 reflex	or	 reduce	 incidence	of	 aspiration	pneumonia	 in	dys-
phagic patients. However, the underlying therapeutic mechanisms 
of action of these drugs are poorly understood. One mechanism is 
stimulation	of	afferent	neural	pathways	for	swallowing,	for	example	
receptors	(TRPV1,	TRPA1	and	TRPM8)	located	in	the	oropharynx,34 
through TRP channel agonists.14- 22 Another mechanism involves in-
creasing the level of or decreasing degradation of substance P, which 
is	a	neuropeptide	known	to	enhance	the	swallow	reflex,35 through 
capsaicin, ACE inhibitors or beta blockers.17,30,31,36 Levodopa and 
dopaminergic agents may improve swallowing through improving 
dopamine metabolism.23-	26	Some	studies	have	also	suggested	that	
treating	coexisting	esophageal	dysphagia	or	facilitating	stroke	recov-
ery may result in overall improvement in swallowing function.27-	29,32 
Finally,	physostigmine	may	improve	swallowing	in	patients	with	pro-
gressive supranuclear palsy through cholinergic stimulation actions, 
but no significant effect has been reported.33
Given the scarce knowledge of the therapeutic potentials of 
pharmacological agents, this systematic review and meta- analysis 
aimed to analyze their group effects on swallowing- related outcomes 
in	 neurogenic	 oropharyngeal	 dysphagia	 from	 existing	 randomized	
controlled	trials	(RCTs).	Further	subgroup	analysis	was	carried	out	to	
analyze the effects of these agents on stroke patients as strokes are 
the commonest cause of neurogenic dysphagia. The findings from 
our meta- analysis should provide insights into the future research 
directions on pharmacological interventions for dysphagia.
2  |  MATERIAL S AND METHODS
This review of data followed the Preferred Reporting Items for 
Systematic	 Reviews	 and	Meta-	Analyses	 (PRISMA)	 guidelines.	 Two	
reviewers	performed	the	search	for	studies,	data	extraction	and	risk	
of bias assessment independently. Data synthesis was carried out 
by one reviewer and verified by a second reviewer. Disagreements 
were resolved by consensus among all authors.
2.1  |  Study identification and search method
We	searched	the	following	electronic	databases	from	January	1970	
to	 March	 2021:	 PubMed,	 EMBASE	 (via	 Ovid),	 CINAHL	 plus	 and	
Cochrane Library. Citations from identified papers were tracked and 
systematic reviews were searched manually for relevant references. 
The terms used for searches included dysphagia, swallowing disor-
ders, deglutition disorders, swallowing, deglutition, pharmaceutical, 
drug, agent, medication and pharmacotherapy.
2.2  |  Eligibility criteria
We	included	only	RCTs	that	compared	pharmacological	intervention	
with placebo intervention for neurogenic oropharyngeal dysphagia. 
Case studies, open- label studies, animal studies, observational stud-




• Transient receptor potential (TRP) agonists showed 
benefit in neurogenic dysphagia. Nifedipine and 
Metoclopramide	 may	 have	 therapeutic	 potential,	 but	
data are limited.
• Dysphagic stroke appeared to benefit more from TRP 
agonists than other pharmacological agents.
• Larger randomised controlled trials on pharmacother-
apy for neurogenic dysphagia are warranted.
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2.2.1  |  Participants
Studies	 with	 adult	 patients	 with	 neurogenic	 oropharyngeal	 dys-
phagia (ie, dysphagia resulted from damage or deterioration of the 
central or peripheral nervous system) as determined clinically or 
through validated self- report questionnaires regardless of the time 
of	 onset	were	 included.	 Studies	with	 healthy	 volunteers,	 patients	
without dysphagia or patients with esophageal dysphagia only were 
not	 considered.	 For	 studies	 that	 included	 both	 patients	 with	 and	
without dysphagia, only data from patients who were considered 
dysphagic, based on modified diet or at an elevated risk of aspiration 
pneumonia	were	extracted	and	analyzed.
2.2.2  |  Interventions
We	 included	 studies	 that	 compared	 pharmaceutical	 interventions	
with placebo intervention. Trials with multiple interventions (eg, 
co- administration of pharmacological agents and other swallowing 
therapies) were eligible if the study groups only differed by the use 
of the target pharmaceutical intervention of interest.
2.2.3  |  Outcomes
Study	 outcomes	 related	 to	 swallowing,	 which	 included	 swallow-
ing physiology measurement, clinical swallowing function ratings, 
functional dysphagia symptom scales or health outcomes related to 
swallowing	functions,	for	example	incidence	of	aspiration	pneumo-
nia,	were	included	for	comparisons.	Studies	that	used	non-	validated	
subjective rating of swallowing ability as an outcome measure were 
excluded.
2.3  |  Data extraction
The	 data	 extracted	 included:	 demographic	 information	 of	 partici-
pants (age and patient characteristics), intervention protocol (drug 
strength	and	dosage	regimen),	outcomes	(mean	[standard	deviation;	
SD]	or	mean	[95%	confidence	interval;	95%	CI])	and	sample	sizes.	For	
studies with multiple outcome measures, the most relevant primary 
swallowing- related outcome was used. If data were not provided, we 
attempted to contact the corresponding authors. If data were pre-
sented in figures and raw data was not obtainable from the authors, 
an	 online	 plot	 digitalizer	 program	 (WebPlotDigitizer	 4.3;	 https://
apps.autom	eris.io/wpd/;	 USA)	 was	 used	 to	 extract	 graphic	 data.	
If data were not obtainable for quantification and analysis despite 
these	attempts,	the	study	was	excluded	from	the	review.
2.4  |  Risk of bias assessment
Seven	 domains	 of	 risk	 of	 bias	 of	 RCTs	 were	 evaluated	 using	 the	
Cochrane	 Collaboration's	 tool	 for	 assessing	 risk	 of	 bias.37 These 
include random sequence generation, allocation concealment, blind-
ing of participants and personnel, blinding of outcome assessment, 
incomplete data, selective reporting and other sources of bias. Two 
reviewers rated the risk of bias of the included studies indepen-
dently. Any disagreement on the judgements was discussed and re-
solved among all authors.
2.5  |  Statistical analysis
All	statistical	analyzes	were	performed	by	Review	Manager	5.4	soft-
ware	program	(RevMan;	Cochrane	Collaboration,	Oxford,	UK).	The	
F I G U R E  1 Flow	diagram	for	study	identification	and	inclusion.
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included	 group	 sizes,	 group	 mean	 differences	 and	 pooled	 SDs.	
Pooled	SD	was	calculated	using	the	following	formula	38:
Confidence	 intervals	 (CIs)	 were	 converted	 to	 SDs	 as	 sug-
gested in the Cochrane Handbook.37	For	outcome	measures	that	




fects model analysis. The significance level was set at p <	0.05	and	
the	effect	sizes	were	presented	as	SMD	[95%	CI].	For	the	 inter-
pretation	of	effect	sizes,	SMD	of	0.2	represented	a	small	effect,	















npre + npost − 2
TA B L E  1 Characteristics	of	included	studies.
Study
Pharmacological 
agent Drug strength; Dosage regimen Comparison Patient characteristics Sample size
Age (years)
Mean (SD) Follow- up schedule Swallowing- related outcome
TRPV1,	TRPA1	and	TRPV8	agonists
44 Capsaicin 10μM	(oral);	Single	dose Active vs placebo 
(cross- over)
Stroke 12 74.3	(7.8) Immediately post PAS
14 Capsaicin 150μM	(oral);	2×/day for 21 days Active vs placebo Stroke 46/46 58.7	(7.4) Immediately post SSA
16 Capsaicin 0.025%	ointment	on	external	auditory	
canal;	Single	dose
Active vs placebo Elderly with stroke or PD 10/10 80.3	(7.7) 5,	30	and	60	minutes	post ESS
18 Capsaicin a. 10 ml of 10 μM	(oral);	Single	dose
b. 10 ml of 10 μM	(oral);	10	days
a. Active vs placebo
b. Active vs placebo







19 Capsaicin (Thermal tactile stimulation +nectar 
bolus)
150	μM/L;	3x/day	for	21	days
Capsaicin vs distilled water Stroke 30/30 65.0	(12.0) Immediately post SSA
20 Capsaicin 1 to 0.1 μM	(oral);	3x/day	for	28	days Active vs placebo Elderly 16/18 81.9	(1.4) Immediately post LTSR





Stroke 34/33 85.0	(5.5) Immediately post LTSR
15 Menthol 10mM,	1mM	and	100μM	menthol	
(oral);	Single	dose
Distilled water vs various 
menthol concentrations
vs cold distilled water 
(cross- over)
Elderly 14 88	(3) Immediately post LTSR
Angiotensin- converting enzyme (ACE) inhibitors
30 Lisinopril 2.5	mg	(oral);	1x/day	for	26	days Active vs placebo Stroke	patients	with	
tube- feeding






Active vs placebo Stroke	patients	with	
silent aspiration
42/12 Not reported Immediately post Number of patients with 
silent aspiration
Calcium blocking agents
27 Nifedipine 30	mg	(oral);	1x/day	for	28	days Active vs placebo Stroke 6/8 77.0	(6.3) Immediately post Pharyngeal transit time
Dopamine D2 receptor antagonists
29 Metoclopramide 10	mg	(oral);	3x/day	for	21	days Active vs placebo Stroke	patients	with	
NGT and without 
pneumonia
30/30 78.1	(8.8) Immediately post Number of episodes of 
pneumonia
Acetylcholinesterase Inhibitors
33 Physostigmine 1.25	± 0.2 mg (optimal dose for each 
patient);	6x/day	for	10	days
Active vs placebo 
(cross- over)
PSP 8 64	(2.4) 3rd or 4th day Swallow	duration
Nitric	oxide	donors
32 Glyceryl trinitrate 
(GTN)
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was	assessed	with	Cochrane's	Q statistic and I2 test in which het-
erogeneity was considered substantial with p <	0.05	and	I2 higher 
than	50%.
3  |  RESULTS
Figure	1	 shows	 the	 flow	diagram	of	 study	 identification.	A	 total	
of	 501	 studies	were	 identified	 from	 4	 electronic	 databases	 and	
7	from	other	sources,	of	which	458	studies	were	considered	po-




omized controlled trial, non- relevant study population, no placebo 
intervention	and	no	target	outcomes	of	relevance.	Fourteen	stud-
ies met the inclusion criteria and were included in systematic re-
view and meta- analysis.
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18 Capsaicin a. 10 ml of 10 μM	(oral);	Single	dose
b. 10 ml of 10 μM	(oral);	10	days
a. Active vs placebo
b. Active vs placebo







19 Capsaicin (Thermal tactile stimulation +nectar 
bolus)
150	μM/L;	3x/day	for	21	days
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Calcium blocking agents
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NGT and without 
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3.1  |  Study characteristics
The	 included	 studies	were	 all	 published	between	1998	and	2020.	
The total number of patients included in this meta- analysis was 
2186.	 Eight	 studies	 investigated	 the	 treatment	 effects	 of	 TRP	
channel	 agonists	 (TRPV1,	 TRPA1	 and	 TRPM8	 agonists)	 with	 327	
patients. One study investigated each of the following pharmaco-
logical agents: Lisinopril (ACE inhibitor; n =	 71),	 Imidapril	 hydro-
chloride (ACE inhibitor; n =	54),	Nifedipine	(calcium	blocking	agent;	
n =	14),	Metoclopramide	(dopamine	D2	receptor	antagonist;	n	=	60),	
Physostigmine (acetylcholinesterase inhibitor; n =	 8)	 and	Glyceryl	
Trinitrate	 (GTN;	nitric	oxide	donor;	n	=	 1652).	The	mean	age	 (SD)	
across	all	patients	was	70.8	(12.2)	years.	Patients	included	in	these	
studies had oropharyngeal dysphagia associated with stroke, aging, 
Parkinson's	disease	or	progressive	supranuclear	palsy.	Table	1	sum-
marizes the characteristics of all included studies.
3.2  |  Risk of bias assessment
The	 risk	 of	 bias	 assessment	 result	 is	 presented	 in	 Figures	 2	 and	
3.	 Most	 studies	 had	 a	 low	 risk	 of	 selection	 and	 detection	 bias.	
Approximately	half	of	the	included	studies	had	a	high	risk	of	per-
formance bias due to the lack of blinding of personnel or partici-
pants.	Attribution	bias	was	high	in	25%	of	the	studies	because	of	
dropouts or deaths during the studies. Reporting bias was low for 
all but one study18 which did not report the outcomes of their 
control group in one of their sub- studies. There was insufficient 
information to determine other risks so these could not be further 
quantified.
3.3  |  Outcome measures
The outcome measures used varied across studies. The most used 
outcome measures were clinical evaluation tools of swallowing 
functions,	 including	 Standardized	 Swallowing	 Assessment	 (SSA)39 
and	 Royal	 Brisbane	 Hospital	 Outcome	 Measure	 for	 Swallowing	
(RBHOS),40 as well as dysphagia severity and swallowing safety eval-
uated based on instrumental evaluation, which included endoscopic 
swallowing scoring41	and	Penetration	Aspiration	Scale	(PAS).42	Five	
studies used timing of swallowing events, including pharyngeal tran-
sit time, swallow duration and the time between onset of bolus en-
tering	the	pharynx	and	triggering	of	swallowing	reflex	(latent	time	of	
swallowing	response;	LTSR).	The	number	of	episodes	of	aspiration	
pneumonia and number of patients with silent aspiration were used 
in	2	studies.	Finally,	one	study	used	feeding	route,	which	was	quanti-
fied	by	a	scale	comprising	7	levels	including,	1:	normal	diet;	2:	soft	
diet; 3: nasogastric tube; 4: percutaneous endoscopic gastrostomy 
tube;	5:	intravenous	or	subcutaneous	fluids;	6:	no	feeding/fluids	and	
7:	death32,43 as a clinical outcome measure.
3.4  |  Adverse events
Regarding serious adverse events, one study reported significantly 
higher mortality in the intervention (Lisinopril) group, which led to 
the premature termination of the study.30	Worsening	of	heart	failure,	
flushing and giddiness were reported in the study with Nifedipine,27 
although the relationships between these events and Nifedipine 
were not discussed by the authors. The GTN study reported that pa-
tients in the intervention group were more likely to have headache 
or clinical hypotension than the control group.32 No serious adverse 




3.6  |  Meta- analysis
3.6.1  |  Effects of pharmacological agents compared to 
placebo interventions
Among all drug classes, TRP channel agonists were studied most 
extensively	with	8	RCTs.	Therefore,	a	pooled	effect	size	was	com-
puted for these agents. The results showed that TRPV1, TRPA1 and 
TRPM8	agonists	yielded	a	large	effect	size	with	substantial	hetero-
geneity	(SMD	[95%	CI]	=1.27	[0.74,	1.80],	p < 0.001; I2 =	79%)	when	
F I G U R E  2 Risk	of	bias	graph	for	all	
included studies.
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compared	to	placebo	intervention	(Figure	4).	Sensitivity	analysis	was	
thus carried out. The heterogeneity was slightly reduced (I2 =	73%)	
when the study by Ebihara et al.,22 which employed a cross- over de-
sign and was the only study that did not use TRPV1 agonist, and the 
study by Cabib et al.,44 which employed a cross- over design and had 
high	risk	of	randomization	bias	were	excluded.	The	resulting	pooled	
effect	 size	 remained	 large	 after	 adjustment	 (SMD	 [95%CI]	 =1.24 
[0.85,	1.99];	p < 0.001).
For	 the	other	pharmacological	agents	 (Figure	5),	only	 single	or	
dual studies were evaluable, making interpretation less meaningful. 
Overall, the pooled effect size for these agents was non- significant 
(SMD	[95%	CI]	=0.25	[−0.24,	0.73];	p = 0.31; I2 =	85%).	When	the	
effects of each drug class were analyzed separately, large and signif-
icant	effect	sizes	were	observed	for	Nifedipine	(SMD	[95%	CI]	=1.13 
[0.09,	 2.18];	p =	 0.03)	 and	Metoclopramide	 (SMD	 [95%	CI]	=1.68	
[1.08,	2.27];	p <	0.001).	By	contrast,	the	pooled	effect	size	of	ACE	
inhibitors (Lisinopril and Imidapril hydrochloride) was non- significant 
and	negatively	associated	with	beneficial	swallowing	outcome	(SMD	






3.6.2  |  Effects of pharmacological agents on post- 
stroke dysphagia
Given that stroke was the most studied disease group among all in-
cluded	studies	 (67%),	a	 further	analysis	was	carried	out	 (Figure	6).	
TRP channel agonists showed a moderate pooled effect size with 
substantial	heterogeneity	(SMD	[95%	CI]	=0.74	[0.10,	1.39];	p = 0.02; 
I2 =	82%).	The	effects	of	other	agents	were	analyzed	as	a	group	be-




This systematic review and meta- analysis evaluated the effects of 
pharmacological agents on swallowing- related outcomes in (neu-
rogenic) dysphagic patients. Among all drug classes, TRP channel 
agonists,	 predominantly	 capsaicin	 (TRPV1	 agonist),	were	most	 ex-
tensively	studied.	We	found	that	overall,	TRPV1,	TRPA1	and	TRPM8	
agonists are superior to placebo interventions with large effect sizes. 
The positive effects included reduced latency of swallowing re-
sponse	and	dysphagia	severity.	By	contrast,	there	are	limited	number	
of RCTs for other pharmacological agents such that their effective-
ness remains questionable. Indeed, the pooled effect size of these 
agents	 was	 non-	significant.	 When	 each	 drug	 class	 was	 analyzed	
separately, calcium blocking agents (Nifedipine) and dopamine D2 
receptor	antagonists	(Metoclopramide)	showed	large	effect	sizes.	By	
comparison, ACE inhibitors (Lisinopril and Imidapril hydrochloride), 
acetylcholinesterase	 inhibitors	 (Physostigmine)	and	nitric	oxide	do-
nors	(GTN)	showed	no	effects.	Subgroup	analysis	on	stroke	patients	
showed that the pooled effect size of TRPV channel agonists was 
moderate whereas the effects of other agents were non- significant. 
Adverse effects including increased mortality, worsening of heart 
failure, flushing, giddiness, headache and clinical hypotension were 
F I G U R E  3 Risk	of	bias	summary	for	individual	studies.
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reported in studies with Lisinopril, Nifedipine and GTN. Our findings 
provided insights into the role and clinical value of pharmacological 
interventions for dysphagia which merits further discussion.
The functional changes following TRP channel agonists treat-
ments	may	be	a	result	of	neuroplastic	changes	induced	in	the	cortex	
by peripheral sensory stimulation of the corresponding receptors in 
the	oropharynx.	Sensory	inputs	are	vital	for	triggering	of	swallow-
ing as well as modulating motor swallowing response.45,46 The oral 
and pharyngeal areas contain receptors that provide central nervous 
system	information	about	texture,	temperature,	taste	and	dynamics	
F I G U R E  4 Forest	plot	showing	pooled	effects	of	transient	receptor	potential	channel	(transient	receptor	potential	vanilloid	1	[TRPV1],	
transient	receptor	potential	ankyrin	1	[TRPA1]	and	transient	receptor	potential	melastatin	8	[TRPM8])	agonists	compared	to	placebo	
interventions	in	patients	with	neurogenic	dysphagia	associated	with	stroke,	aging,	Parkinson's	disease	or	progressive	supranuclear	palsy.
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of a food bolus as it passes along the swallowing tract.46,47 TRPV1, 
TRPA1	and	TRPM8	are	examples	of	afferent	receptors	innervated	by	
cranial nerves (trigeminal; CN V, glossopharyngeal; CN IX, vagus; CN 
X).34 They are sensitive to a range of temperatures and chemicals. 
TRPV1 can be activated by “hot” pepper (capsaicin) or heat (> 43℃) 
whereas	 TRPA1	 and	TRPM8	 can	 be	 activated	 by	 cold	 stimuli.48,49 
TRPA1 responds to pungent stimuli such as wasabi or mustard and 
(unpleasant) low temperature (<	17°C);	associated	with	burning	pain	
sensation	 in	 extreme	 cold.50,51	 TRPM8	 responds	 to	milder	 stimuli	
such	 as	menthol	 and	 temperature	 (25–	28°C).50,51 These receptors 
belong to the sub- families of TRP channels. TRPs are cationic chan-
nels	 expressed	 at	 the	 plasma	 membrane	 which	 when	 activated,	
allow Ca2+ ions to enter and depolarize sensory neurons.49 This leads 
to triggering of sensory impulses, which are then transmitted to the 
nucleus	tractus	solitarius	(NTS)	of	the	medulla	and	the	sensorimotor	
cortex	through	interneuronal	connections.45,46
Preliminary neurophysiological evidence appears to support the 
hypothesis that functional changes induced by TRP agonists are cen-
trally mediated. Using electroencephalography (EEG), Tomsen et al.18 
demonstrated that oral capsaicin increased cortical event- related 
potentials in cingulate gyrus and medial frontal gyrus during swal-
lowing, indicating an improved conduction and integration of sen-
sory	 information	 into	the	cortex.	Such	neurophysiological	changes	
were associated with improved swallowing responses in elderly pa-
tients	with	 oropharyngeal	 dysphagia.	Moreover,	 Cabib	 et	 al.44 re-
ported	enhancement	in	excitability	of	the	motor	cortex,	albeit	with	
no functional improvements, after oral capsaicin treatment in stroke 
patients. The lack of functional changes may be due to the low dos-
age (10μM;	single	dose)	used	for	chronic	 (> 3 months) post- stroke 
dysphagia.	By	comparison,	 a	 recent	 study	with	healthy	volunteers	
found that despite inducing changes in swallowing biomechanics, 
oral capsaicin did not alter cortical activation patterns as revealed by 
magnetoencephalography	(MEG).52 This negative finding may reflect 
the dual effects of capsaicin where the immediate pharyngeal swal-
low response may be improved by single dose administration, but 
long- term neuromodulatory effects may only be induced through re-
petitive stimulation. Nonetheless, these findings provided valuable 
insights into the neurophysiological effects and dose- dependency 
of TRP channel agonists. Large scale, multicenter clinical trials are 
warranted to further investigate the optimal dose for sustained neu-
rophysiological and functional improvements.
Apart from sending sensory impulses to the central nervous sys-
tem, TRPV1 agonists may modulate swallowing through releasing 
substance	P,	which	is	a	neuropeptide	that	enhances	cough	reflex.53 
Studies	have	found	that	reduced	levels	of	substance	P	are	associated	
with an increased risk of aspiration pneumonia in elderly patients,35 
stroke patients54,55	 and	patients	with	Parkinson's	disease.56 Given 
that an increase in serum substance P level after capsaicin treatment 
has been reported in some RCTs,14,15 it is possible that this neuro-
peptide may play a role in the observed improvements in swallowing 
function. The mechanisms of TRPV1 agonists on the release of sub-
stance P and the relationship between substance P and swallowing 
function	are	not	 fully	understood.	 In	healthy	volunteers,	 Suntrup-	
Krueger	et	al.52 found that the effects on salivary substance P level 
are dose dependent, where an increase was only detected with high 
dose	(50μM)	but	not	low	dose	(10μM)	oral	capsaicin.	In	elderly	pa-
tients with dysphagia, a recent RCT found that increased levels of 
substance P is associated with improvement in swallowing efficiency 
following capsaicin treatment.17	Some	studies	have	explored	the	re-
lationship between substance P and the physiology of swallowing. 
Tomsen et al.57 found that elderly patients with oropharyngeal dys-
phagia showed impaired pharyngeal sensitivity compared to healthy 
F I G U R E  6 Forest	plot	showing	pooled	effects	of	(A)	transient	receptor	potential	channel	(transient	receptor	potential	vanilloid	1	[TRPV1],	
transient	receptor	potential	ankyrin	1	[TRPA1]	and	transient	receptor	potential	melastatin	8	[TRPM8])	agonists	and	(B)	other	agents	
compared to placebo interventions in stroke patients with dysphagia.
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volunteers and substance P level was negatively correlated with 
pharyngeal	 sensory	 threshold.	Moreover,	 in	 acute	 stroke	patients,	
low substance P level was associated with low frequency of spon-
taneous swallowing and increased incidence of pneumonia.55 These 
findings suggested that substance P level is closely related to swal-
lowing performance and may be a potential marker for pharyngeal 
sensitivity or stroke- related aspiration pneumonia.
Previous reports have suggested that ACE inhibitors may be 
beneficial to dysphagic patients by reducing degradation and in-
activation of substance P.58 Arai et al.54 suggested that Imidapril 
hydrochloride may increase substance P and reduce the risk of si-
lent aspiration in stroke patients, although the effect size was non- 
significant in our meta- analysis. In contrast, Lee et al.30 found that 
Lisinopril did not lower the risk of aspiration pneumonia nor improve 
swallowing functions. Concerningly, they also found a higher mor-
tality rate in the active intervention group. Although these studies 
emphasized that the dose used was lower than the standard dose for 
hypertensive treatment, caution must be taken when administrating 
these drugs to avoid systemic effects on blood pressure, the cardio-
vascular and renal systems.
Our review found that there are very limited number of RCTs 
that investigate the effects of calcium blocking agents, dopamine 
D2 receptor antagonists, acetylcholinesterase inhibitors and nitric 
oxide	donors	on	swallowing.	Positive	 findings	have	been	 reported	
for the former two agents, but underlying mechanisms remain 
largely speculative.27,29 Nifedipine is a calcium blocking agent that 
can be used to alleviate chest pain and rapidly lower blood pres-
sure.59 Perez et al.27 postulated that Nifedipine may improve pha-
ryngeal	dysphagia	through	reducing	coexisting	esophageal	spasm	or	
through	 global	 enhancement	 on	 stroke	 recovery.	Metoclopramide	
is a dopamine antagonist used to reduce nausea and vomiting.60 
Warusevitane	 et	 al.29 suggested several possible mechanisms of 
Metoclopramide	 in	 reducing	 incidence	 of	 aspiration	 pneumonia.	
These include reduced regurgitation through increasing the tone of 
lower esophageal sphincter and accelerating gastric emptying in pa-
tients	with	nasogastric	tube-	feeding.	By	contrast,	negative	findings	
were reported for Physostigmine (acetylcholinesterase inhibitor) in 
patients with progressive supranuclear palsy. The authors argued 
that the dose used was not sufficient to inhibit acetylcholinester-








baseline data for dysphagic patients were not reported. GTN is a 
type	 of	 nitric	 oxide	 donor	 used	 to	 treat	 high	 blood	 pressure	 and	
heart failure and its early administration may have beneficial effects 
for stroke patients.61,62	Woodhouse	et	al.32 proposed that the ob-
served improvements on feeding route may be driven by a general 
facilitation of stroke recovery, rather than mechanisms specific for 
swallowing.	Animal	studies	have	shown	that	nitric	oxide	is	important	
for initiation of swallowing and esophageal peristalsis.63 It is possible 
that	nitric	oxide	donors	may	improve	swallowing	reflex	through	sup-
plying	nitric	 oxide	 exogenously,	 although	 this	 explanation	 remains	
speculative without pharmacodynamic evidence. Notwithstanding, 
some subtle treatment effects may have been missed in this rather 
more	restrictive	meta-	analysis.	More	RCTs	are	warranted	for	these	
pharmacological agents before they could be considered as potential 
interventions for dysphagia.
Our subgroup analysis showed that TRP channel agonists ap-
peared to have larger positive effects for stroke patients com-
pared to other pharmacological agents. Neuroplasticity, which is 
the reorganization of neural networks in response to damages or 
disruptions,	plays	an	important	role	in	stroke	recovery.	Specifically,	
improvement in swallowing function in unilateral stroke patients 
is driven by an increase in the cortical representation of the un-
damaged hemisphere.64 This might provide unique opportunities 
for pharmacological agents to alter outcome beyond peripheral ef-
fects. The positive neurophysiological effects reported with TRP 
channel agonists18,44	may	 explain	 the	 larger	 effects	 compared	 to	
other agents. However, cautions must be taken when interpreting 
this result because of the high heterogeneity and a smaller num-
ber	of	RCTs	for	other	agents	than	TRP	channel	agonists.	Similarly,	
although the effects of these agonists appeared to be smaller in 
stroke patients than in patients with neurogenic dysphagia, the dif-
ference may be attributed to the smaller number of trials in stroke 
patients.	Moreover,	a	mixed	population	of	stroke	patients	with	dif-
ferent severity and chronicity were studied in these RCTs. A recent 
meta- analysis showed that the effects of neurostimulation treat-
ments varied according to the chronicity of stroke.65 Therefore, it 
is plausible that the stroke characteristics may have influenced the 
responsiveness to TRP channel agonists, hence limiting their treat-
ment efficacy in stroke patients.
The quality of studies included in our meta- analysis was 
considered moderate due to the high risk of performance bias. 
Approximately	half	of	 the	 included	studies	did	not	have	 reliable	
blinding of participants or personnel. These were primarily stud-
ies	with	TRP	channel	agonists.	While	blinding	 is	 ideally	done	by	
delivering a placebo treatment that appears identical to the ac-
tive treatment, it can be challenging for some compounds with 
strong, distinctive taste and smell such as TRP channel agonists. 
Moreover,	 placebo	 treatment	 may	 not	 be	 available	 from	manu-
facturers62 such that a control condition that resembles the ac-
tive treatment needs to be made from other materials, which may 
influence its validity. The use of an active control may minimize 
performance bias, but in some cases, single- blinded designs may 
be unavoidable.
Our	review	is	limited	by	the	small	number	of	studies.	For	some	
drug classes, only one RCT was eligible for analysis, making it dif-
ficult to draw any definitive conclusions regarding their efficacies. 
Given the small number, the risk of publication bias cannot be eval-
uated.	Moreover,	 only	 English	 studies	 were	 included	 for	 analysis.	
Lastly, patient characteristics, outcome measures and intervention 
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protocols of included studies were highly heterogeneous. Therefore, 
our results must be interpreted with some caution.
In conclusion, our systematic review found that TRPV1, TRPA1 
and	 TRPM8	 agonists	 have	 beneficial	 effects	 for	 patients	 with	
neurogenic oropharyngeal dysphagia when compared to placebo 
interventions. There are very limited number of RCTs for other 
pharmacological agents, including ACE inhibitors, calcium blocking 
agents, dopamine D2 receptor antagonists, acetylcholinesterase 
inhibitors	and	nitric	oxide	donors.	Therefore,	the	treatment	effects	
of	 these	 drugs	 remain	 uncertain.	 Major	 adverse	 effects	 reported	
include increased mortality, worsening of heart failure, flushing, 
giddiness, headache and hypotension in clinical trials with Lisinopril, 
Nifedipine and GTN. Overall, the level of evidence for pharmacolog-
ical interventions for neurogenic oropharyngeal dysphagia remains 
low.	Future	 large	 scale,	multicenter	 clinical	 trials	 are	warranted	 to	
fully	explore	the	potential	of	these	agents.
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